Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Intention to treat analysis of 68Ga-PSMA and 11C-choline PET/CT versus CT for prostate cancer recurrences after surgery.

Schwenck J, Olthof SC, Pfannenberg C, Reischl G, Wegener D, Marzec J, Bedke J, Stenzl A, Nikolaou K, la Fougère C, Zips D, Müller AC.

J Nucl Med. 2019 Mar 8. pii: jnumed.118.224543. doi: 10.2967/jnumed.118.224543. [Epub ahead of print]

PMID:
30850491
2.

68 Ga-PSMA-PET for radiation treatment planning in prostate cancer recurrences after surgery: Individualized medicine or new standard in salvage treatment.

Habl G, Sauter K, Schiller K, Dewes S, Maurer T, Eiber M, Combs SE.

Prostate. 2017 Jun;77(8):920-927. doi: 10.1002/pros.23347. Epub 2017 Mar 20.

PMID:
28317152
3.

68Ga-PSMA-11 PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA <0.5 ng/ml. Efficacy and impact on treatment strategy.

Farolfi A, Ceci F, Castellucci P, Graziani T, Siepe G, Lambertini A, Schiavina R, Lodi F, Morganti AG, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):11-19. doi: 10.1007/s00259-018-4066-4. Epub 2018 Jun 15.

PMID:
29905907
4.

Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy.

Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L.

J Nucl Med. 2015 Aug;56(8):1185-90. doi: 10.2967/jnumed.115.160382. Epub 2015 Jun 25.

5.

68Ga-PSMA-11 PET/CT in recurrent prostate cancer: efficacy in different clinical stages of PSA failure after radical therapy.

Ceci F, Castellucci P, Graziani T, Farolfi A, Fonti C, Lodi F, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):31-39. doi: 10.1007/s00259-018-4189-7. Epub 2018 Oct 22.

PMID:
30350010
6.

Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG.

BMC Cancer. 2019 Jan 7;19(1):18. doi: 10.1186/s12885-018-5200-1. Erratum in: BMC Cancer. 2019 Jan 21;19(1):97.

7.

Impact of 68Ga-PSMA PET/CT on salvage radiotherapy planning in patients with prostate cancer and persisting PSA values or biochemical relapse after prostatectomy.

Bluemel C, Linke F, Herrmann K, Simunovic I, Eiber M, Kestler C, Buck AK, Schirbel A, Bley TA, Wester HJ, Vergho D, Becker A.

EJNMMI Res. 2016 Dec;6(1):78. Epub 2016 Oct 26.

8.

(68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment.

van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, Nguyen Q, Ho B, Emmett L.

BJU Int. 2016 May;117(5):732-9. doi: 10.1111/bju.13397. Epub 2016 Jan 24.

9.

Patterns of failure after radical prostatectomy in prostate cancer - implications for radiation therapy planning after 68Ga-PSMA-PET imaging.

Schiller K, Sauter K, Dewes S, Eiber M, Maurer T, Gschwend J, Combs SE, Habl G.

Eur J Nucl Med Mol Imaging. 2017 Sep;44(10):1656-1662. doi: 10.1007/s00259-017-3746-9. Epub 2017 Jun 23.

PMID:
28646463
10.

Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.

Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.

Radiat Oncol. 2017 Nov 10;12(1):176. doi: 10.1186/s13014-017-0902-0.

11.

68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy.

Tan JSH, Goh CXY, Koh YS, Li Y, Tuan JKL, Chua ET, Tan TWK, Wang MLC, Lee LS, Tay KJ, Kanesvaran R, Toh CK, Tong AKT, Lam WWC, Chua MLK.

Cancer Biol Med. 2019 Feb;16(1):157-166. doi: 10.20892/j.issn.2095-3941.2018.0288.

PMID:
31119056
12.

Clinicopathological predictors of positive 68Ga-PSMA-11 PET/CT in PSA-only recurrence of localized prostate cancer following definitive therapy.

Aydin AM, Haberal B, Artykov M, Bilen CY, Yazici S.

Ann Nucl Med. 2019 May;33(5):326-332. doi: 10.1007/s12149-019-01340-1. Epub 2019 Feb 18.

PMID:
30778860
13.

Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.

Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.

Strahlenther Onkol. 2018 Apr;194(4):303-310. doi: 10.1007/s00066-017-1231-9. Epub 2017 Nov 13.

PMID:
29134231
14.

Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT.

Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, Pfannenberg C, la Fougère C.

Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):92-101. Epub 2016 Aug 24.

PMID:
27557844
15.

68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.

Bluemel C, Krebs M, Polat B, Linke F, Eiber M, Samnick S, Lapa C, Lassmann M, Riedmiller H, Czernin J, Rubello D, Bley T, Kropf S, Wester HJ, Buck AK, Herrmann K.

Clin Nucl Med. 2016 Jul;41(7):515-21. doi: 10.1097/RLU.0000000000001197.

16.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13.

17.

A Prospective, Multi-site, International Comparison of F-18 fluoro-methyl-choline, multi-parametric magnetic resonance and Ga-68 HBED-CC (PSMA-11) in men with High-Risk Features and Biochemical Failure after Radical Prostatectomy: Clinical Performance and Patient Outcomes.

Emmett L, Metser U, Bauman G, Hicks RJ, Weickhardt A, Davis ID, Punwani S, Pond GR, Chua SS, Ho B, Johnston E, Pouliot F, Scott A.

J Nucl Med. 2018 Nov 15. pii: jnumed.118.220103. doi: 10.2967/jnumed.118.220103. [Epub ahead of print]

PMID:
30442757
18.

Detection Rate of 18F-choline-PET/CT and 68Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes.

Jilg CA, Drendel V, Rischke HC, Beck TIR, Reichel K, Krönig M, Wetterauer U, Schultze-Seemann W, Meyer PT, Vach W.

J Nucl Med. 2019 Jan 25. pii: jnumed.118.220541. doi: 10.2967/jnumed.118.220541. [Epub ahead of print]

PMID:
30683768
19.

Treatment Outcomes from 68Ga-PSMA PET/CT-Informed Salvage Radiation Treatment in Men with Rising PSA After Radical Prostatectomy: Prognostic Value of a Negative PSMA PET.

Emmett L, van Leeuwen PJ, Nandurkar R, Scheltema MJ, Cusick T, Hruby G, Kneebone A, Eade T, Fogarty G, Jagavkar R, Nguyen Q, Ho B, Joshua AM, Stricker P.

J Nucl Med. 2017 Dec;58(12):1972-1976. doi: 10.2967/jnumed.117.196683. Epub 2017 Jul 26.

20.

68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

Grubmüller B, Baltzer P, D'Andrea D, Korn S, Haug AR, Hacker M, Grubmüller KH, Goldner GM, Wadsak W, Pfaff S, Babich J, Seitz C, Fajkovic H, Susani M, Mazal P, Kramer G, Shariat SF, Hartenbach M.

Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242. doi: 10.1007/s00259-017-3858-2. Epub 2017 Oct 26.

Supplemental Content

Support Center